1. Home
  2. MNY vs ATNM Comparison

MNY vs ATNM Comparison

Compare MNY & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MoneyHero Limited

MNY

MoneyHero Limited

HOLD

Current Price

$0.55

Market Cap

38.4M

Sector

N/A

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.59

Market Cap

31.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNY
ATNM
Founded
2014
2000
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.4M
31.4M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
MNY
ATNM
Price
$0.55
$1.59
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $3.60
AVG Volume (30 Days)
28.8K
★ 180.1K
Earning Date
12-04-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 14.17
EPS
N/A
★ 0.71
Revenue
N/A
★ $90,000.00
Revenue This Year
N/A
$19,344.45
Revenue Next Year
$17.49
N/A
P/E Ratio
★ N/A
$1.96
Revenue Growth
N/A
★ 11.11
52 Week Low
$0.38
$0.74
52 Week High
$1.60
$1.74

Technical Indicators

Market Signals
Indicator
MNY
ATNM
Relative Strength Index (RSI) 27.09 74.58
Support Level N/A $0.97
Resistance Level $1.52 N/A
Average True Range (ATR) 0.04 0.12
MACD -0.01 0.05
Stochastic Oscillator 51.54 96.92

Price Performance

Historical Comparison
MNY
ATNM

About MNY MoneyHero Limited

MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: